OncoMatch/Clinical Trials/NCT07300150
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
Is NCT07300150 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including PT0511 and Cetuximab for colorectal cancer.
Treatment: PT0511 · Cetuximab — The primary purpose of this study is to evaluate the safety and tolerability, determine the maximally tolerated dose (MTD) and/or recommended Phase 2 dose(s) (RP2D) of PT0511 in adult participants with solid tumors as monotherapy and in combination with cetuximab in participants with colorectal cancer (CRC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Cancer type
Colorectal Cancer
Pancreatic Cancer
Non-Small Cell Lung Carcinoma
Tumor Agnostic
Biomarker criteria
Required: KRAS mutation
any KRAS mutation or wild-type (WT) KRAS amplification identified through molecular testing
Required: KRAS amplification
any KRAS mutation or wild-type (WT) KRAS amplification identified through molecular testing
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Participant must have received at least 1 and no more than 4 prior systemic therapies or be intolerant or ineligible for available therapies known to provide clinical benefit
Cannot have received: KRAS/RAS degrader
Prior treatment with a KRAS/RAS degrader
Lab requirements
Blood counts
Participants with laboratory values indicating inadequate hematology function
Kidney function
Participants with laboratory values indicating inadequate renal function
Liver function
Participants with laboratory values indicating inadequate hepatic function
Participants with laboratory values indicating inadequate hematology, hepatic, or renal function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana-Farber/Massachusetts General Hospital, Inc · Boston, Massachusetts
- New Experimental Therapeutics of San Antonio LLC · San Antonio, Texas
- START - South Texas Accelerated Research Therapeutics, LLC · San Antonio, Texas
- START Mountain Region · West Valley City, Utah
- NEXT Virginia · Fairfax, Virginia
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07300150 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior KRAS/RAS degrader disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS mutation is a required biomarker for enrollment.
Does this trial require KRAS?
Yes, KRAS amplification is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify